Medcaptain Announces Successful Listing on the Main Board of the Hong Kong Stock Exchange

On 7 September 2026, Medcaptain Medical Technology Co., Ltd. (“Medcaptain” or the “Company”) was listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited under stock code 02041. The listing marks an important milestone in Medcaptain’s development and provides a strong platform for the Company’s next phase of international expansion and sustainable growth.

As a global provider of medical devices and solutions, Medcaptain has spent more than a decade serving the healthcare sector. The Company has built a diversified product portfolio across three core areas: life support, minimally invasive intervention and in vitro diagnostics. Its portfolio includes more than 320 product models, comprising over 60 life-support products, more than 110 minimally invasive interventional products and more than 150 in vitro diagnostic products. These products support a broad range of clinical needs across hospital departments, wards and outpatient clinics, as well as community health centres, diagnostic laboratories and home-care settings.

Medcaptain has established an extensive global presence, The company products have cumulatively reached over 140 countries and regions globally. In China, the Company products have cumulatively reached over 6,000 hospitals, including approximately 90% of Grade 3A hospitals, covering 31 provinces, municipalities and autonomous regions.

Looking ahead, Medcaptain will remain focused on innovation, portfolio development and the delivery of competitive medical solutions that address evolving clinical needs worldwide.

The Company will also maintain a disciplined approach to operational excellence, corporate responsibility and sustainable growth, with the aim of creating long-term value for customers, employees, shareholders and the communities it serves.